Matthew L. Sherman, is Executive Vice President and Chief Medical Officer of Deciphera Pharmaceuticals. Dr. Sherman joined Deciphera in 2019 and brings over 25 years of experience as a physician-scientist in clinical drug development in oncology and hematology at leading biotechnology and pharmaceutical companies. Prior to joining Deciphera, Dr. Sherman served as Chief Medical Officer of Acceleron Pharma, Inc., Senior Vice President and Chief Medical Officer at Synta Pharmaceuticals (now Madrigal Pharmaceuticals) and spent over a decade at Wyeth-Ayerst Research/Genetics Institute, where he led the successful submission, positive Oncologic Drug Advisory Committee recommendation, and FDA approval for the first antibody immune-drug conjugate for acute myeloid leukemia. He currently serves as a director of Pieris Pharmaceuticals and is on the Board of Advisors and Alumni Council at the Geisel School of Medicine at Dartmouth. Dr. Sherman is board certified in Internal Medicine and Medical Oncology and has held various academic and teaching positions at Harvard Medical School with corresponding clinical appointments at the Dana-Farber Cancer Institute and Brigham and Women’s Hospital in Boston. Dr. Sherman received a S.B. in Chemistry from the Massachusetts Institute of Technology and a M.D. from Dartmouth Medical School. He completed his internal medicine residency at Georgetown University Medical Center and fellowship in Medical Oncology at the Dana-Farber Cancer Institute.